The FDA [notified consumers and health professionals](http://www.fda.gov/medwatch/safety/2005/safety05.htm#MBI) on November 29, 2005 that MBI Distributing (also known as Molecular Biologics) has signed a [consent decree](http://www.fda.gov/bbs/topics/NEWS/2005/NEW01265.html) to stop manufacturing and distributing over-the-counter eye drops until it corrects manufacturing deficiencies found during FDA inspections.
The problem eye drops include those sold as Oxydrops, Bright Eyes, Bright Eyes II, Clarity Vision for Life, Visitein, and Can-C. The FDA found that the company lacked controls during manufacturing to ensure that the eye drops were sterile. In addition, two brands Visitein and Clarity Vision for Life are unapproved drugs.
The FDA also said that Biogesic, Bio-Ice, and Bio-Heat, over-the-counter pain-relievers sold by MBI, do not provide consumers with adequate warnings for safe use.
The FDA recommends that consumers, health care providers, and caregivers throw out any Oxydrops, Bright Eyes, Bright Eyes II, Clarity Vision for Life, Visitein, and Can-C eye drops as well as Biogesic, Bio-Ice, or Bio-Heat. They should not be used.
Adverse events resulting from the use of the eye drops or pain-relievers should be reported to the MedWatch, the FDA’s voluntary reporting program at 1-800-FDA-1088; by FAX at 1-800-FDA-0178; by mail to MedWatch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD, 20857-9787; or [online.](https://www.accessdata.fda.gov/scripts/medwatch/)